Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Amid a surprisingly severe flu season and a Covid-19 resurgence, those highly contagious respiratory illnesses are drawing the largest share of media coverage and public attention.

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...

Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Mounjaro (tirzepatide) is prescribed to manage blood sugar levels in people with type 2 diabetes. It’s available as a single-dose prefilled pen. You will administer your Mounjaro injections into your ...